{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:03:31Z","timestamp":1790042611838,"version":"4.0.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s13555-017-0174-5","type":"journal-article","created":{"date-parts":[[2017,2,8]],"date-time":"2017-02-08T05:22:38Z","timestamp":1486531358000},"page":"175-179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up"],"prefix":"10.1007","volume":"7","author":[{"given":"Daniel","family":"Ebrahimi-Fakhari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia Sigrid Lissi","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Flotats-Bastardas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pf\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,8]]},"reference":[{"key":"174_CR1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.pcl.2015.03.005","volume":"62","author":"FJ DiMario Jr","year":"2015","unstructured":"DiMario FJ Jr, Sahin M, Ebrahimi-Fakhari D. Tuberous sclerosis complex. Pediatr Clin North Am. 2015;62:633\u201348.","journal-title":"Pediatr Clin North Am"},{"key":"174_CR2","doi-asserted-by":"publisher","unstructured":"Mann L, Ebrahimi-Fakhari D, Heinrich B, Flotats-Bastardas M, Gortner L, von Gontard A, Niemcyzk J, Poryo M, Meyer S. [ESPED-Survey: TSC-disease in children and adolescents: preliminary results from a German epidemiological survey]. Wien Med Wochenschr. 2016. doi: 10.1007\/s10354-016-0522-6 .","DOI":"10.1007\/s10354-016-0522-6"},{"key":"174_CR3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","volume":"372","author":"P Curatolo","year":"2008","unstructured":"Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372:657\u201368.","journal-title":"Lancet"},{"key":"174_CR4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1470-2045(07)70411-4","volume":"9","author":"J Jozwiak","year":"2008","unstructured":"Jozwiak J, Jozwiak S, Wlodarski P. Possible mechanisms of disease development in tuberous sclerosis. Lancet Oncol. 2008;9:73\u20139.","journal-title":"Lancet Oncol."},{"key":"174_CR5","doi-asserted-by":"crossref","first-page":"e0158476","DOI":"10.1371\/journal.pone.0158476","volume":"11","author":"DN Franz","year":"2016","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost MD, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Niolat J, Jozwiak S. Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. PLoS One. 2016;11:e0158476.","journal-title":"PLoS One"},{"key":"174_CR6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaad.2007.05.004","volume":"57","author":"RA Schwartz","year":"2007","unstructured":"Schwartz RA, Fernandez G, Kotulska K, Jozwiak S. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol. 2007;57:189\u2013202.","journal-title":"J Am Acad Dermatol"},{"key":"174_CR7","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.yebeh.2007.07.010","volume":"11","author":"DA Muzykewicz","year":"2007","unstructured":"Muzykewicz DA, Newberry P, Danforth N, Halpern EF, Thiele EA. Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex. Epilepsy Behav. 2007;11:506\u201313.","journal-title":"Epilepsy Behav"},{"key":"174_CR8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pediatrneurol.2016.04.003","volume":"61","author":"S Jozwiak","year":"2016","unstructured":"Jozwiak S, Sadowski K, Kotulska K, Schwartz RA. Topical use of mammalian target of rapamycin (mTOR) inhibitors in tuberous sclerosis complex\u2014a comprehensive review of the literature. Pediatr Neurol. 2016;61:21\u20137.","journal-title":"Pediatr Neurol"},{"key":"174_CR9","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archdermatol.2010.125","volume":"146","author":"AK Haemel","year":"2010","unstructured":"Haemel AK, O\u2019Brian AL, Teng JM. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol. 2010;146:715\u20138.","journal-title":"Arch Dermatol"},{"key":"174_CR10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/ajd.12125","volume":"55","author":"J Tu","year":"2014","unstructured":"Tu J, Foster RS, Bint LJ, Halbert AR. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions. Australas J Dermatol. 2014;55:63\u20139.","journal-title":"Australas J Dermatol"},{"key":"174_CR11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus G. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49:243\u201354.","journal-title":"Pediatr Neurol"},{"key":"174_CR12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11634580-000000000-00000","volume":"12","author":"MK Koenig","year":"2012","unstructured":"Koenig MK, Hebert AA, Roberson J, Samuels J, Slopis J, Woerner A, Northrup H. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin. Drugs R D. 2012;12:121\u20136.","journal-title":"Drugs R D."},{"key":"174_CR13","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1111\/pde.12551","volume":"32","author":"EV Pynn","year":"2015","unstructured":"Pynn EV, Collins J, Hunasehally PR, Hughes J. Successful topical rapamycin treatment for facial angiofibromata in two children. Pediatr Dermatol. 2015;32:e120\u20133.","journal-title":"Pediatr Dermatol"},{"key":"174_CR14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000357033","volume":"228","author":"J Park","year":"2014","unstructured":"Park J, Yun SK, Cho YS, Song KH, Kim HU. Treatment of angiofibromas in tuberous sclerosis complex: the effect of topical rapamycin and concomitant laser therapy. Dermatology. 2014;228:37\u201341.","journal-title":"Dermatology"},{"key":"174_CR15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ad.2013.09.013","volume":"105","author":"N Knopfel","year":"2014","unstructured":"Knopfel N, Martin-Santiago A, Bauza A, Hervas JA. Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis. Actas Dermosifiliogr. 2014;105:802\u20133.","journal-title":"Actas Dermosifiliogr."},{"key":"174_CR16","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1468-3083.2011.04212.x","volume":"26","author":"R Salido","year":"2012","unstructured":"Salido R, Garnacho-Saucedo G, Cuevas-Asencio I, Ruano J, Galan-Gutierrez M, Velez A, Moreno-Gimenez JC. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis\u2014associated facial angiofibroma. J Eur Acad Dermatol Venereol. 2012;26:1315\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"174_CR17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1440-0960.2011.00837.x","volume":"53","author":"RS Foster","year":"2012","unstructured":"Foster RS, Bint LJ, Halbert AR. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients. Australas J Dermatol. 2012;53:52\u20136.","journal-title":"Australas J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-017-0174-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T06:04:59Z","timestamp":1498370699000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13555-017-0174-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,8]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["174"],"URL":"https:\/\/doi.org\/10.1007\/s13555-017-0174-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,8]]}}}